VRCA Stock Summary and Trading Ideas (Verrica Pharmaceuticals | NASDAQ:VRCA)

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals trades on the NASDAQ stock market under the symbol VRCA.

As of February 23, 2026, VRCA stock price declined to $5.61 with 67,612 million shares trading.

VRCA has a beta of 1.46, meaning it tends to be more sensitive to market movements. VRCA has a correlation of 0.04 to the broad based SPY ETF.

VRCA has a market cap of $89.70 million. This is considered a Micro Cap stock.

Last quarter Verrica Pharmaceuticals reported $14 million in Revenue and $.13 earnings per share. This beat revenue expectation by $2 million and exceeded earnings estimates by $1.10.

In the last 3 years, VRCA traded as high as $114.10 and as low as $3.28.

The top ETF exchange traded funds that VRCA belongs to (by Net Assets): VXF, VTI, AVTM.

VRCA has underperformed the market in the last year with a price return of -24.4% while the SPY ETF gained +13.0%. However, in the short term, VRCA had mixed performance relative to the market. It has outperformed in the last 3 months, returning +39.6% vs +4.9% return in SPY. But in the last 2 weeks, VRCA shares have been beat by the market, returning -18.8% compared to an SPY return of -1.2%.

VRCA support price is $5.46 and resistance is $6.12 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRCA shares will trade within this expected range on the day.